April 28, 2026

VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

April 1, 2026

VivoSim Announces Pricing of up to a $4 Million Public Offering

March 24, 2026

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

March 3, 2026

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

February 11, 2026

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

January 29, 2026

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

January 6, 2026

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer